A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastatic melanoma or Metastatic Merkel Cell Carcinoma

Trial Profile

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastatic melanoma or Metastatic Merkel Cell Carcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Pasireotide (Primary) ; Pasireotide (Primary)
  • Indications Malignant melanoma; Merkel cell carcinoma
  • Focus Adverse reactions
  • Acronyms MACS1670
  • Sponsors Novartis
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Status changed to discontinued due to slow recruitment as per results presented at the 41st European Society for Medical Oncology Congress
    • 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top